A dual SGLT1 and SGLT2 inhibitor reduces the risk of cardiovascular and kidney disease in adults with type 1 diabetes

In this MEDtalk Elisabeth Buur Stougaard, MD, PhD-stud. at Steno Diabetes Center, Copenhagen, presents data of sotagliflozin, a dual SGLT1 and SGLT2 inhibitor for treating type 1 diabetes. The study was presented at EASD Congress 2022 and shows that sotagliflozin significantly reduces the estimated risk of cardiovascular and kidney disease in adults with type 1 diabetes.